Medical Treatment of Anxiety
For adults with anxiety disorders, start with an SSRI (selective serotonin reuptake inhibitor) or SNRI (serotonin-norepinephrine reuptake inhibitor) as first-line pharmacotherapy, avoiding benzodiazepines due to their adverse effect profile and long-term risks. 1, 2
First-Line Pharmacological Options
The evidence strongly supports SSRIs and SNRIs as initial pharmacotherapy for anxiety disorders based on their efficacy, tolerability, and lack of significant long-term adverse effects 1, 2. These medications work across multiple anxiety disorder subtypes including generalized anxiety disorder (GAD), panic disorder, and social anxiety disorder 3, 4.
Specific SSRI/SNRI Agents and Dosing
For generalized anxiety disorder, consider:
- Sertraline: Start 25-50 mg/day, titrate weekly as needed
- Fluoxetine: Start 10-20 mg/day
- Fluvoxamine: Start 25-50 mg/day
- SNRIs (venlafaxine, duloxetine): Equally effective alternatives 5, 2
For social anxiety disorder, SSRIs remain first-line, with sertraline and paroxetine having the strongest evidence base 4.
Treatment Duration and Titration
- Adjust doses weekly to achieve optimal response while minimizing side effects 5
- Continue treatment for at least 12 months after achieving remission 2
- Remission can take several months to achieve; stopping medication prematurely increases relapse risk within the first year 6
- When discontinuing, choose a stress-free period and taper gradually 5
What NOT to Use
Benzodiazepines are not recommended despite their rapid anxiolytic effects, due to:
- Risk of dependence and withdrawal
- Cognitive impairment
- Falls risk (especially in older adults)
- Long-term adverse effects outweigh short-term benefits 1
The only acceptable use is short-term bridging while awaiting SSRI/SNRI onset of action, but this should be time-limited 1.
Treatment-Resistant Cases
When first-line SSRIs/SNRIs fail after adequate trial (8-12 weeks at therapeutic dose), consider augmentation strategies 7:
Evidence-Based Augmentation Options:
- Quetiapine: 50-300 mg/day (mean effective dose ~150-386 mg/day) - most studied augmentation agent for GAD 7
- Pregabalin: Mean dose ~222 mg/day - effective for treatment-resistant GAD 7
- Aripiprazole: Start 10 mg/day, mean effective dose ~13.9 mg/day 7
Common pitfall: These augmentation strategies show efficacy but carry metabolic and sedation risks. Monitor weight, sedation, and akathisia closely 7.
Algorithm for Treatment Selection
Subthreshold symptoms (not meeting diagnostic criteria): Start with self-help and behavioral interventions before pharmacotherapy 1
Diagnosed anxiety disorder:
- First choice: SSRI or SNRI
- Consider patient preference, comorbidities, and prior treatment history
- If comorbid depression present, antidepressants are superior to benzodiazepines 6
Inadequate response after 8-12 weeks at therapeutic dose:
- Switch to alternative SSRI/SNRI, OR
- Add augmentation agent (quetiapine, pregabalin, or aripiprazole) 7
Monitor for treatment-emergent adverse events: headaches, gastrointestinal symptoms, behavioral activation, worsening anxiety, or suicidal ideation (particularly in younger patients) 5
Special Populations
Elderly or medically ill patients: Reduce starting doses and titrate more cautiously 6
Refractory cases: May require dose increases above standard ranges, but balance against tolerability 6
Perinatal period: Requires specialized consideration with risk-benefit analysis of medication continuation versus discontinuation 8
Integration with Behavioral Treatment
While this focuses on pharmacotherapy, cognitive-behavioral therapy (CBT) is equally first-line and can be combined with medication for enhanced outcomes 1, 9. The combination of CBT plus sertraline shows superior efficacy compared to either alone 5.